(TRIAL ONGOING) This non-randomized clinical study, that commenced on 6 April 2020, is trialling HBOT-treatment of 40 COVID-19 positive patients with respiratory distress. Each patient is receiving a 90-minute session of hyperbaric oxygen, with subsequent sessions at the discretion of patient and the medical team. After each treatment, the patient is returned to the medical unit and continues with standard care. Patients receive up to a total of five HBOT sessions. At completion of the HBOT-intervention phase, these 40 patients’ outcomes are being compared to patients receiving standard (non-HBOT) care only.